Seroatlas · Human Serome Atlas

LRRTM2

Leucine-rich repeat transmembrane neuronal protein 2

Also known as: KIAA0416, LRRT2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
O43300
Gene
LRRTM2
Ensembl
ENSG00000146006
Chromosome
5
Canonical length
516 aa
Protein class
Predicted intracellular proteins, Predicted membrane proteins

OverviewNCBI Gene

Predicted to enable neurexin family protein binding activity. Predicted to be involved in regulation of postsynaptic density assembly. Predicted to act upstream of or within several processes, including long-term synaptic potentiation; negative regulation of receptor internalization; and positive regulation of synapse assembly. Is active in GABA-ergic synapse and postsynaptic specialization membrane. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

516 residues, UniProt reviewed canonical sequence.

>O43300|LRRTM2
     1  MGLHFKWPLG APMLAAIYAM SMVLKMLPAL GMACPPKCRC EKLLFYCDSQ GFHSVPNATD
    61  KGSLGLSLRH NHITELERDQ FASFSQLTWL HLDHNQISTV KEDAFQGLYK LKELILSSNK
   121  IFYLPNTTFT QLINLQNLDL SFNQLSSLHP ELFYGLRKLQ TLHLRSNSLR TIPVRLFWDC
   181  RSLEFLDLST NRLRSLARNG FAGLIKLREL HLEHNQLTKI NFAHFLRLSS LHTLFLQWNK
   241  ISNLTCGMEW TWGTLEKLDL TGNEIKAIDL TVFETMPNLK ILLMDNNKLN SLDSKILNSL
   301  RSLTTVGLSG NLWECSARIC ALASWLGSFQ GRWEHSILCH SPDHTQGEDI LDAVHGFQLC
   361  WNLSTTVTVM ATTYRDPTTE YTKRISSSSY HVGDKEIPTT AGIAVTTEEH FPEPDNAIFT
   421  QRVITGTMAL LFSFFFIIFI VFISRKCCPP TLRRIRQCSM VQNHRQLRSQ TRLHMSNMSD
   481  QGPYNEYEPT HEGPFIIING YGQCKCQQLP YKECEV

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against LRRTM2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
1
Mean surface accessibility (rSASA)
0.38
Highest tissue expression
16 nTPM

Expression across tissuesHPA

Tissue

  • cerebral cortex: 16 nTPM
  • basal ganglia: 6.8 nTPM
  • hypothalamus: 6.5 nTPM
  • cerebellum: 6.4 nTPM
  • hippocampal formation: 6.1 nTPM
  • amygdala: 5.2 nTPM

Single-cell type

  • epicardial cells: 80 nCPM
  • cardiomyocytes: 72 nCPM
  • oligodendrocyte progenitor cells: 40 nCPM
  • brain inhibitory neurons: 34 nCPM
  • oligodendrocytes: 26 nCPM
  • brain excitatory neurons: 24 nCPM

Immune cell

  • basophil: 0 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM
  • gdT-cell: 0 nTPM
  • intermediate monocyte: 0 nTPM
  • MAIT T-cell: 0 nTPM

Brain region

  • cerebral cortex: 50 nTPM
  • white matter: 48 nTPM
  • basal ganglia: 43 nTPM
  • thalamus: 42 nTPM
  • hippocampal formation: 37 nTPM
  • hypothalamus: 34 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.42
gnomAD pLI
0.81
gnomAD missense Z
1.89
DepMap mean gene effect
0.02
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of LRRTM2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads LRRTM2 as an antibody target. Whether an autoantibody or antibody against LRRTM2 could matter depends on whether native LRRTM2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

LRRTM2 is annotated at the cell surface, where native LRRTM2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label LRRTM2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/LRRTM2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...